Our group and others have previously reported that RAS mutation is an independent prognostic factor in MM [24], and that NRAS mutation significantly reduces MM sensitivity to single-agent bortezomib therapy [25]. The gene discussed is NRAS; the disease is Miyoshi myopathy.